Helixgate https://validator.w3.org/feed/docs/rss2.html REGENXBIO slumps after serious side effects mar Duchenne gene therapy results STAT+: BeOne wins FDA approval in lymphoma race Biogen takes tau Alzheimer’s therapy to Phase 3 despite mid-stage fail, prompting cautious optimism How Penn Medicine plans to use AI to train their doctors Biotech leaders pitch Pazdur as next FDA chief Degron adds $40M to series A, supporting immunology plans for molecular glue platform STAT+: Three years of declining overdose deaths begets cautious optimism and some concerns Biogen’s anti-tau Alzheimer’s drug misses Phase 2 goal, but claims signs of efficacy Visualizing Receptor Transport Within Neurons via Transcytosis BeOne wins mantle cell lymphoma approval, opening new therapy class Hantavirus risk remains low, CDC says, citing its ‘playbook’ response  BMS, Hengrui Pharma Partner on 13 Programs in Up-to-$15.2B Collaboration Takeda’s ‘transformation program’ leaves 4,500 jobless STAT+: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta From MSCs to iPSCs: building the cell therapy future Opinion: Using AI in addiction medicine could be particularly risky Hiring outlook: job opportunities on BioSpace rise YOY, but layoffs affect thousands 17 companies hiring in California Webinar: Resolving Target Biology and Compound MOA at Scale: Enabling AI to Chat with Cells on the BioGPU Runtime ASGCT President Terry Flotte Touts Rare Disease Initiatives as His Term Ends Officials say $1.3 billion in Medicaid money to California will be deferred over suspicions of fraud After an apparent cure, a gene editing company struggles to repeat the magic ApexGO: AI-Driven Approach to Faster Antibiotic Discovery Bora inks $122.5M takeover of MacroGenics facility to further US expansion Opinion: Hospitals are silencing doctors online, and it’s fueling the health misinformation crisis Valneva to cut up to 15% of jobs as reduced travel hits vaccine demand STAT+: What the Trump administration wants in its next FDA leader Why AI Alone Isn’t Enough for Oligonucleotide Discovery Cellares and ProTgen Automate Manufacturing of Progenitor T-Cell Therapy for Blood Cancer U.S. overdose deaths fell again in 2025, but some worry about policy and drug supply changes New InFocus eReport: Advances in cancer research FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Abeona pivots to T cells; AstraZeneca’s rare disease drug passes Phase 3 Goodbye Galapagos: chameleon company exits the island, rebrands as Lakefront Lilly data point to ‘maintenance’ strategies for GLP-1 weight loss UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged “It Was Not a Cure”: Musunuru Cautions ASGCT on Baby KJ Promise Post-Hoc: Why FDA Commissioner Marty Makary was ousted Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B ASGCT 2026: Victoria Gray Roadshow Returns to Boston New subpoena suggests DOJ has begun criminal investigation of gender-affirming care Makary’s out at FDA, Sanofi’s priority voucher issues, top exec pay Behind Galapagos’ transformation into Lakefront Biotherapeutics Degron, CREATE, TenNor raise capital; Cabaletta posts CAR-T data Icon opens early-phase research unit in San Antonio, plus satellite clinics to grow trial capabilities Lilly maintains weight loss leadership as Foundayo, Zepbound keep pounds off after switching After ‘most damaging period in FDA history,’ Makary will be hard to replace Tessera reveals strongest data yet for in vivo sickle cell therapy Home